[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhuyboGlQON56N1iH3ktFpJ1LHjVjJ2v6f9p9n-0Io4Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Royal Marsden NHS Foundation Trust",[4],267,false,53,11,10075987,29,189,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Breast Cancer",33,{"name":18,"count":19},"Cancer",17,{"name":21,"count":22},"Prostate Cancer",16,{"name":24,"count":25},"Head and Neck Cancer",14,{"name":27,"count":28},"Colorectal Cancer",9,{"name":30,"count":28},"Lung Cancer",{"name":32,"count":28},"Ovarian Cancer",{"name":34,"count":35},"Cervical Cancer",8,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03867799","iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer","2022-10-21","Nivolumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02560636","Pembrolizumab in Muscle Invasive\u002FMetastatic Bladder Cancer","2025-01-15","Pembrolizumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04166721","WaKING: Wnt and checKpoint INhibition in Gastric Cancer","2025-03-30","Atezolizumab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT02678182","Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial","2025-04-17","Capecitabine",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06560905","Preoperative Planning With PSMA-PET in Melanoma Surgery Trial","2025-12-31","68Ga-PSMA",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05644457","Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck","2026-04","Circulating tumour DNA dynamics",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04360941","PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","2026-07-31","Palbociclib",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT02998567","Combination Study of Guadecitabine\u002FASTX727 and Pembrolizumab","2026-09","Guadecitabine",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06250036","Zimberelimab Anti-PD1 +\u002F- Domvanalimab in Resectable Mmrd Gastric Cancer","2027-03-20","Single agent zimberelimab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04920708","Fulvestrant, Ipatasertib and CDK4\u002F6 Inhibition in Metastatic ER+\u002FHER2- Breast Cancer Patients Without ctDNA Suppression","2027-06","Ipatasertib 300mg",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,151,195,213,231,249,267,293,311,343,361,379,397,415,433,453,475,500,518,536,554,675,724,742,760,778,797,822,847,871,894,920,938,966,1027,1059,1099,1129,1151,1173,1203,1226,1244,1262,1280,1304,1328,1351,1369,1387,1412,1435,1461,1479,1503,1521,1539,1557,1580,1605,1623,1645,1669,1693,1711,1735,1757,1782,1806,1831,1858,1876,1894,1912,1930,1948,1966,1984,2002,2028,2046,2072,2094,2117,2143,2166,2184,2209,2227,2252,2270,2288,2306,2331,2357,2382,2400,2447,2473,2500,2525,2549,2573,2591,2618],{"intervention":56,"totalTrials":96,"cells":97},3,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":144,"soonestReadout":55},[105,119,132],{"nctId":53,"briefTitle":54,"status":106,"phases":107,"primaryCompletion":55,"completion":85,"start":108,"enrollment":109,"conditions":110,"interventions":114},"ACTIVE_NOT_RECRUITING",[90],"2015-02",494,[111,112,113],"Adenocarcinoma of the Oesophagus","Adenocarcinoma of the Gastro-oesophageal Junction","Adenocarcinoma of the Stomach",[56,115,116,117,118],"MEDI4736","Trastuzumab","Rucaparib","Ramucirumab",{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":108,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT01022541","Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer","COMPLETED",[90],"2010-12","2006-06",47,[128],"Metastatic Colorectal Cancer",[56,130,131],"Oxaliplatin","Bevacizumab",{"nctId":133,"briefTitle":134,"status":135,"phases":136,"start":137,"enrollment":138,"conditions":139,"interventions":140},"NCT00383695","Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer","UNKNOWN",[90],"2005-09",164,[27],[141,142,143],"cetuximab","capecitabine","oxaliplatin",1,{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"intervention":41,"totalTrials":96,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":189,"PHASE4":191,"NA":193},{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":144,"soonestReadout":40},[159,171,182],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT02446860","A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)","TERMINATED",[90],"2018-08","2015-04",15,[168],"Renal Cell Carcinoma",[170],"nivolumab",{"nctId":172,"briefTitle":173,"status":122,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":11,"conditions":178,"interventions":181},"NCT03383302","SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects",[89,90],"2024-08-12","2025-06-26","2018-02-08",[179,180],"Non-small Cell Lung Cancer Stage II","Non-small Cell Lung Cancer Stage I",[41],{"nctId":38,"briefTitle":39,"status":106,"phases":183,"primaryCompletion":40,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":188},[90],"2024-09","2019-03-27",25,[128],[41],{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":100},[],{"intervention":115,"totalTrials":144,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":144,"soonestReadout":55},[203],{"nctId":53,"briefTitle":54,"status":106,"phases":204,"primaryCompletion":55,"completion":85,"start":108,"enrollment":109,"conditions":205,"interventions":206},[90],[111,112,113],[56,115,116,117,118],{"trials":208,"activeCount":100},[],{"trials":210,"activeCount":100},[],{"trials":212,"activeCount":100},[],{"intervention":116,"totalTrials":144,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":225,"PHASE4":227,"NA":229},{"trials":216,"activeCount":100},[],{"trials":218,"activeCount":100},[],{"trials":220,"activeCount":144,"soonestReadout":55},[221],{"nctId":53,"briefTitle":54,"status":106,"phases":222,"primaryCompletion":55,"completion":85,"start":108,"enrollment":109,"conditions":223,"interventions":224},[90],[111,112,113],[56,115,116,117,118],{"trials":226,"activeCount":100},[],{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":100},[],{"intervention":117,"totalTrials":144,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":144,"soonestReadout":55},[239],{"nctId":53,"briefTitle":54,"status":106,"phases":240,"primaryCompletion":55,"completion":85,"start":108,"enrollment":109,"conditions":241,"interventions":242},[90],[111,112,113],[56,115,116,117,118],{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":100},[],{"trials":248,"activeCount":100},[],{"intervention":118,"totalTrials":144,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":261,"PHASE4":263,"NA":265},{"trials":252,"activeCount":100},[],{"trials":254,"activeCount":100},[],{"trials":256,"activeCount":144,"soonestReadout":55},[257],{"nctId":53,"briefTitle":54,"status":106,"phases":258,"primaryCompletion":55,"completion":85,"start":108,"enrollment":109,"conditions":259,"interventions":260},[90],[111,112,113],[56,115,116,117,118],{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"intervention":81,"totalTrials":144,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":270,"activeCount":100},[],{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":144,"soonestReadout":80},[275],{"nctId":78,"briefTitle":79,"status":276,"phases":277,"primaryCompletion":80,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":285},"RECRUITING",[90],"2031-09-01","2025-02-20",50,[282,283,284],"Locally Advanced Gastric Adenocarcinoma","MSI-H\u002FdMMR Gastric Cancer","MSI-H\u002FdMMR Gastroesophageal-junction Cancer",[81,286],"Combination zimberelimab + domvanalimab",{"trials":288,"activeCount":100},[],{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"intervention":286,"totalTrials":144,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":296,"activeCount":100},[],{"trials":298,"activeCount":100},[],{"trials":300,"activeCount":144,"soonestReadout":80},[301],{"nctId":78,"briefTitle":79,"status":276,"phases":302,"primaryCompletion":80,"completion":278,"start":279,"enrollment":280,"conditions":303,"interventions":304},[90],[282,283,284],[81,286],{"trials":306,"activeCount":100},[],{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":100},[],{"intervention":312,"totalTrials":144,"cells":313},"Palbociclib 125Mg Tab",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":100},[],{"trials":319,"activeCount":144,"soonestReadout":324},[320],{"nctId":321,"briefTitle":322,"status":276,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":331},"NCT04985266","A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer",[90],"2027-09-01","2030-09-01","2022-03-30",1100,[329,330],"ER+ Breast Cancer","HER2-negative Breast Cancer",[312,332,333,334,335,336],"Fulvestrant","Tamoxifen","Letrozole","Exemestane","Anastrozole",{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"intervention":332,"totalTrials":144,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":144,"soonestReadout":324},[351],{"nctId":321,"briefTitle":322,"status":276,"phases":352,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":353,"interventions":354},[90],[329,330],[312,332,333,334,335,336],{"trials":356,"activeCount":100},[],{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":100},[],{"intervention":333,"totalTrials":144,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":364,"activeCount":100},[],{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":144,"soonestReadout":324},[369],{"nctId":321,"briefTitle":322,"status":276,"phases":370,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":371,"interventions":372},[90],[329,330],[312,332,333,334,335,336],{"trials":374,"activeCount":100},[],{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":100},[],{"intervention":334,"totalTrials":144,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":144,"soonestReadout":324},[387],{"nctId":321,"briefTitle":322,"status":276,"phases":388,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":389,"interventions":390},[90],[329,330],[312,332,333,334,335,336],{"trials":392,"activeCount":100},[],{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"intervention":335,"totalTrials":144,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":144,"soonestReadout":324},[405],{"nctId":321,"briefTitle":322,"status":276,"phases":406,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":407,"interventions":408},[90],[329,330],[312,332,333,334,335,336],{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":100},[],{"intervention":336,"totalTrials":144,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":100},[],{"trials":422,"activeCount":144,"soonestReadout":324},[423],{"nctId":321,"briefTitle":322,"status":276,"phases":424,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":425,"interventions":426},[90],[329,330],[312,332,333,334,335,336],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":100},[],{"intervention":61,"totalTrials":144,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":436,"activeCount":100},[],{"trials":438,"activeCount":100},[],{"trials":440,"activeCount":144,"soonestReadout":60},[441],{"nctId":58,"briefTitle":59,"status":276,"phases":442,"primaryCompletion":60,"completion":60,"start":443,"enrollment":22,"conditions":444,"interventions":446},[90],"2025-03-11",[445],"Malignant Melanoma",[61],{"trials":448,"activeCount":100},[],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"intervention":51,"totalTrials":144,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":144,"soonestReadout":50},[461],{"nctId":48,"briefTitle":49,"status":106,"phases":462,"primaryCompletion":50,"completion":60,"start":463,"enrollment":464,"conditions":465,"interventions":468},[89,90],"2020-02-11",52,[466,467],"Metastatic Esophageal Cancer","Metastatic Gastric Cancer",[51],{"trials":470,"activeCount":100},[],{"trials":472,"activeCount":100},[],{"trials":474,"activeCount":100},[],{"intervention":86,"totalTrials":144,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":100},[],{"trials":482,"activeCount":144,"soonestReadout":85},[483],{"nctId":83,"briefTitle":84,"status":106,"phases":484,"primaryCompletion":85,"completion":85,"start":485,"enrollment":486,"conditions":487,"interventions":490},[90],"2022-12-28",57,[488,329,489],"Metastatic Breast Cancer","Advanced Breast Cancer",[86,491,492,493],"Fulvestrant 500g","Palbociclib 75mg-125mg","CDK4\u002F6 Inhibitor",{"trials":495,"activeCount":100},[],{"trials":497,"activeCount":100},[],{"trials":499,"activeCount":100},[],{"intervention":491,"totalTrials":144,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":512,"PHASE4":514,"NA":516},{"trials":503,"activeCount":100},[],{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":144,"soonestReadout":85},[508],{"nctId":83,"briefTitle":84,"status":106,"phases":509,"primaryCompletion":85,"completion":85,"start":485,"enrollment":486,"conditions":510,"interventions":511},[90],[488,329,489],[86,491,492,493],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":100},[],{"intervention":492,"totalTrials":144,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":521,"activeCount":100},[],{"trials":523,"activeCount":100},[],{"trials":525,"activeCount":144,"soonestReadout":85},[526],{"nctId":83,"briefTitle":84,"status":106,"phases":527,"primaryCompletion":85,"completion":85,"start":485,"enrollment":486,"conditions":528,"interventions":529},[90],[488,329,489],[86,491,492,493],{"trials":531,"activeCount":100},[],{"trials":533,"activeCount":100},[],{"trials":535,"activeCount":100},[],{"intervention":493,"totalTrials":144,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":539,"activeCount":100},[],{"trials":541,"activeCount":100},[],{"trials":543,"activeCount":144,"soonestReadout":85},[544],{"nctId":83,"briefTitle":84,"status":106,"phases":545,"primaryCompletion":85,"completion":85,"start":485,"enrollment":486,"conditions":546,"interventions":547},[90],[488,329,489],[86,491,492,493],{"trials":549,"activeCount":100},[],{"trials":551,"activeCount":100},[],{"trials":553,"activeCount":100},[],{"intervention":46,"totalTrials":9,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":639,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":557,"activeCount":100},[],{"trials":559,"activeCount":599,"soonestReadout":45},[560,573,583,593,603,612,623,631],{"nctId":561,"briefTitle":562,"status":563,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":100,"conditions":568,"interventions":570},"NCT04279938","A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed\u002FRefractory DLBCL","WITHDRAWN",[89],"2020-03","2021-01","2018-09",[569],"Relapsed or Refractory Diffuse Large B-cell Lymphoma",[571,46,572],"Tinostamustinein","Rituximab",{"nctId":574,"briefTitle":575,"status":162,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT04166734","Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma",[89],"2023-07-25","2021-02-12",5,[581],"Advanced Malignant Pleural Mesothelioma",[46],{"nctId":584,"briefTitle":585,"status":122,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT02587455","Pembrolizumab and Palliative Radiotherapy in Lung",[89],"2021-08-20","2016-06-24",24,[591],"Thoracic Tumours",[46],{"nctId":594,"briefTitle":595,"status":162,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":602},"NCT03436056","PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients",[89],"2019-07-08","2018-03-01",2,[601],"Metastatic Non-small-cell lunG Cancer",[46],{"nctId":604,"briefTitle":605,"status":162,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":144,"conditions":609,"interventions":611},"NCT03144466","A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer",[89],"2019-01-31","2017-12-18",[610],"Cervix Cancer",[46],{"nctId":613,"briefTitle":614,"status":162,"phases":615,"primaryCompletion":616,"completion":616,"start":617,"enrollment":96,"conditions":618,"interventions":621},"NCT02819752","PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck",[89],"2019-11-28","2017-07-12",[619,620],"Squamous Cell Carcinoma of the Head and Neck","Squamous Cell Carcinoma",[46,622],"Chemotherapy",{"nctId":43,"briefTitle":44,"status":106,"phases":624,"primaryCompletion":45,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},[89],"2028-07-30","2016-06-06",34,[629],"Invasive Bladder Cancer",[46],{"nctId":73,"briefTitle":74,"status":106,"phases":632,"primaryCompletion":75,"completion":75,"start":633,"enrollment":634,"conditions":635,"interventions":637},[89],"2017-01-26",60,[636],"Non Small Cell Lung Cancer",[76,46,638],"ASTX727",{"trials":640,"activeCount":100},[641,651,660],{"nctId":642,"briefTitle":643,"status":122,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":186,"conditions":647,"interventions":649},"NCT03123276","Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma",[89,90],"2022-05-20","2017-11-29",[648],"Sarcoma",[46,650],"Gemcitabine",{"nctId":652,"briefTitle":653,"status":563,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":100,"conditions":657,"interventions":659},"NCT02663258","A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)",[90],"2017-07-19","2016-01",[658],"Advanced Melanoma",[46],{"nctId":661,"briefTitle":662,"status":162,"phases":663,"primaryCompletion":565,"completion":664,"start":665,"enrollment":19,"conditions":666,"interventions":668},"NCT02562625","Trial of Pembrolizumab and Radiotherapy in Melanoma",[90],"2021-10","2016-08-11",[667],"Melanoma",[46],{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"intervention":676,"totalTrials":96,"cells":677},"Avelumab",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":692,"PHASE3":705,"PHASE4":720,"NA":722},{"trials":679,"activeCount":100},[],{"trials":681,"activeCount":144,"soonestReadout":70},[682],{"nctId":68,"briefTitle":69,"status":276,"phases":683,"primaryCompletion":70,"completion":70,"start":684,"enrollment":685,"conditions":686,"interventions":691},[89],"2020-08-11",45,[687,688,689,488,329,690],"Triple Negative Breast Cancer","Locally Advanced Breast Cancer","Recurrent Breast Cancer","HER2-positive Breast Cancer",[71,676],{"trials":693,"activeCount":100},[694],{"nctId":695,"briefTitle":696,"status":135,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT03812796","Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)",[90],"2021-11-30","2019-01-11",75,[18,702],"GI Cancer",[704,676],"Domatinostat",{"trials":706,"activeCount":100},[707],{"nctId":708,"briefTitle":709,"status":162,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":719},"NCT03827044","Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer",[91],"2021-01-05","2022-01-05","2018-08-31",30,[716,717,718],"POLE Exonuclease Mutant Colon Cancer","Microsatellite Instability","Stage III Colon Cancer",[676],{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":100},[],{"intervention":76,"totalTrials":144,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":144,"soonestReadout":75},[730],{"nctId":73,"briefTitle":74,"status":106,"phases":731,"primaryCompletion":75,"completion":75,"start":633,"enrollment":634,"conditions":732,"interventions":733},[89],[636],[76,46,638],{"trials":735,"activeCount":100},[],{"trials":737,"activeCount":100},[],{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":100},[],{"intervention":638,"totalTrials":144,"cells":743},{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":745,"activeCount":100},[],{"trials":747,"activeCount":144,"soonestReadout":75},[748],{"nctId":73,"briefTitle":74,"status":106,"phases":749,"primaryCompletion":75,"completion":75,"start":633,"enrollment":634,"conditions":750,"interventions":751},[89],[636],[76,46,638],{"trials":753,"activeCount":100},[],{"trials":755,"activeCount":100},[],{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"intervention":71,"totalTrials":144,"cells":761},{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":144,"soonestReadout":70},[766],{"nctId":68,"briefTitle":69,"status":276,"phases":767,"primaryCompletion":70,"completion":70,"start":684,"enrollment":685,"conditions":768,"interventions":769},[89],[687,688,689,488,329,690],[71,676],{"trials":771,"activeCount":100},[],{"trials":773,"activeCount":100},[],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"intervention":66,"totalTrials":144,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":790},{"trials":781,"activeCount":100},[],{"trials":783,"activeCount":100},[],{"trials":785,"activeCount":100},[],{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":100},[],{"trials":791,"activeCount":144,"soonestReadout":65},[792],{"nctId":63,"briefTitle":64,"status":276,"phases":793,"primaryCompletion":65,"completion":65,"start":794,"enrollment":280,"conditions":795,"interventions":796},[],"2022-03-09",[24],[66],{"intervention":798,"totalTrials":144,"cells":799},"Molecular Analyses",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":100},[],{"trials":811,"activeCount":144,"soonestReadout":816},[812],{"nctId":813,"briefTitle":814,"status":276,"phases":815,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":821},"NCT05808920","The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck",[],"2028-04-30","2029-04-30","2023-09-08",400,[24],[798],{"intervention":823,"totalTrials":144,"cells":824},"Molecular Analysis",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":144,"soonestReadout":841},[837],{"nctId":838,"briefTitle":839,"status":276,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":843,"conditions":844,"interventions":846},"NCT05933889","Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer",[],"2027-08","2023-12-19",250,[845],"Cancer Head Neck",[823],{"intervention":848,"totalTrials":144,"cells":849},"DNA sequencing, RNA gene expression analysis, molecular profiling",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":100},[],{"trials":859,"activeCount":100},[],{"trials":861,"activeCount":144,"soonestReadout":866},[862],{"nctId":863,"briefTitle":864,"status":276,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":870},"NCT05734963","ORganoid GeneratioN Study for Cancer",[],"2031-04-12","2022-04-04",100,[18],[848],{"intervention":872,"totalTrials":144,"cells":873},"Irinotecan, Capecitabine",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":892},{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[884],{"nctId":885,"briefTitle":886,"status":122,"phases":887,"start":888,"enrollment":16,"conditions":889,"interventions":891},"NCT00220168","Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed\u002FRefractory Upper GI Tumours",[92],"2003-01",[890],"Upper Gastrointestinal Tumours",[872],{"trials":893,"activeCount":100},[],{"intervention":895,"totalTrials":144,"cells":896},"epirubicin, oxaliplatin, capecitabine",{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":916,"NA":918},{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[],{"trials":904,"activeCount":100},[905],{"nctId":906,"briefTitle":907,"status":162,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":914},"NCT00824785","REAL3 Trial of Efficacy of EOX With\u002FWithout Panitumumab in Previously Untreated Adv OG Cancer",[91],"2013-02","2008-05",574,[913],"Oesophago-gastric Cancer",[895,915],"EOX + panitumumab",{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"intervention":915,"totalTrials":144,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":934,"NA":936},{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[930],{"nctId":906,"briefTitle":907,"status":162,"phases":931,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":932,"interventions":933},[91],[913],[895,915],{"trials":935,"activeCount":100},[],{"trials":937,"activeCount":100},[],{"intervention":939,"totalTrials":144,"cells":940},"Human Growth hormone",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":962,"NA":964},{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"trials":946,"activeCount":100},[],{"trials":948,"activeCount":100},[949],{"nctId":950,"briefTitle":951,"status":122,"phases":952,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":961},"NCT00300664","A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.",[90,91],"2005-04","2002-07",150,[957,958,959,960],"Multiple Myeloma","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndrome",[939],{"trials":963,"activeCount":100},[],{"trials":965,"activeCount":100},[],{"intervention":967,"totalTrials":96,"cells":968},"Cisplatin",{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":100},[],{"trials":974,"activeCount":100},[975,989,1001],{"nctId":976,"briefTitle":977,"status":135,"phases":978,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":985},"NCT02051868","International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel",[90],"2017-08","2018-02","2013-12",80,[984],"Squamous Cell Carcinoma of the Anus",[967,986,987,988],"5-Fluorouracil","Carboplatin","Paclitaxel",{"nctId":990,"briefTitle":991,"status":135,"phases":992,"primaryCompletion":980,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT02060656","Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)",[90],"2023-08","2013-09",92,[997],"Diffuse Large B-Cell Lymphoma",[650,999,572,967,1000],"Methylprednisolone","Lenalidomide",{"nctId":1002,"briefTitle":1003,"status":135,"phases":1004,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1015},"NCT01719835","CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study",[90],"2016-11-30","2022-08","2012-03",87,[1010,1011,1012,1013,1014],"Peripheral T-cell Lymphoma NOS","Anaplastic Large Cell Lymphoma, ALK-Negative","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic Gamma\u002F Delta T-cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma",[1016,650,1017,1018,1019,1020,967],"Cyclophosphamide","Doxorubicin","Vincristine","Prednisolone","methylprednisolone",{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"trials":1026,"activeCount":100},[],{"intervention":130,"totalTrials":96,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1043,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[1033],{"nctId":1034,"briefTitle":1035,"status":122,"phases":1036,"primaryCompletion":124,"completion":124,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT01048320","Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer",[89],"2006-07",36,[1040],"Advanced Pancreatic Cancer",[650,130,1042],"Imatinib",{"trials":1044,"activeCount":100},[1045,1049],{"nctId":120,"briefTitle":121,"status":122,"phases":1046,"primaryCompletion":124,"completion":108,"start":125,"enrollment":126,"conditions":1047,"interventions":1048},[90],[128],[56,130,131],{"nctId":133,"briefTitle":134,"status":135,"phases":1050,"start":137,"enrollment":138,"conditions":1051,"interventions":1052},[90],[27],[141,142,143],{"trials":1054,"activeCount":100},[],{"trials":1056,"activeCount":100},[],{"trials":1058,"activeCount":100},[],{"intervention":1060,"totalTrials":599,"cells":1061},"Olaparib",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1078,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":100},[1066],{"nctId":1067,"briefTitle":1068,"status":122,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":634,"conditions":1073,"interventions":1075},"NCT02338622","Trial of Olaparib in Combination With AZD5363 (ComPAKT)",[89],"2016-03-21","2017-03-21","2014-03-31",[1074],"Advanced Cancer",[1076,1077],"olaparib","AZD5363",{"trials":1079,"activeCount":100},[1080],{"nctId":1081,"briefTitle":1082,"status":135,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1092},"NCT03829345","A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer",[90],"2021-02-14","2022-02-14","2019-07-02",54,[1089,1090,1091],"Oesophageal Cancer","Gastro-Oesophageal Junction Cancer","Gastric Cancer",[1060],{"trials":1094,"activeCount":100},[],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"intervention":1100,"totalTrials":599,"cells":1101},"cytogenetic analysis",{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[],{"trials":1107,"activeCount":100},[1108,1116],{"nctId":1109,"briefTitle":1110,"status":135,"phases":1111,"start":1112,"enrollment":634,"conditions":1113,"interventions":1114},"NCT00082979","Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer",[90],"2003-10",[15],[1100,1115],"proteomic profiling",{"nctId":1117,"briefTitle":1118,"status":135,"phases":1119,"start":1120,"enrollment":868,"conditions":1121,"interventions":1122},"NCT00083018","Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer",[90],"2003-09",[15],[1100,1115],{"trials":1124,"activeCount":100},[],{"trials":1126,"activeCount":100},[],{"trials":1128,"activeCount":100},[],{"intervention":1115,"totalTrials":599,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[1137,1141],{"nctId":1109,"briefTitle":1110,"status":135,"phases":1138,"start":1112,"enrollment":634,"conditions":1139,"interventions":1140},[90],[15],[1100,1115],{"nctId":1117,"briefTitle":1118,"status":135,"phases":1142,"start":1120,"enrollment":868,"conditions":1143,"interventions":1144},[90],[15],[1100,1115],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[],{"intervention":999,"totalTrials":599,"cells":1152},{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[1159,1163],{"nctId":990,"briefTitle":991,"status":135,"phases":1160,"primaryCompletion":980,"completion":993,"start":994,"enrollment":995,"conditions":1161,"interventions":1162},[90],[997],[650,999,572,967,1000],{"nctId":1002,"briefTitle":1003,"status":135,"phases":1164,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1165,"interventions":1166},[90],[1010,1011,1012,1013,1014],[1016,650,1017,1018,1019,1020,967],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"intervention":1016,"totalTrials":599,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1197,"PHASE4":1199,"NA":1201},{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":100},[1181,1185],{"nctId":1002,"briefTitle":1003,"status":135,"phases":1182,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1183,"interventions":1184},[90],[1010,1011,1012,1013,1014],[1016,650,1017,1018,1019,1020,967],{"nctId":1186,"briefTitle":1187,"status":122,"phases":1188,"completion":137,"start":1189,"conditions":1190,"interventions":1191},"NCT00004237","Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer",[90],"1998-10",[15],[1192,1193,1194,1195,1196],"cyclophosphamide","doxorubicin hydrochloride","epirubicin hydrochloride","mitoxantrone hydrochloride","vinorelbine tartrate",{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":100},[],{"trials":1202,"activeCount":100},[],{"intervention":1204,"totalTrials":144,"cells":1205},"Capecitabine, Oxaliplatin",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[1212],{"nctId":1213,"briefTitle":1214,"status":122,"phases":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1219},"NCT00220116","Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer",[90],"2002-08",172,[27],[1204],{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":100},[],{"intervention":986,"totalTrials":144,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1229,"activeCount":100},[],{"trials":1231,"activeCount":100},[],{"trials":1233,"activeCount":100},[1234],{"nctId":976,"briefTitle":977,"status":135,"phases":1235,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":1236,"interventions":1237},[90],[984],[967,986,987,988],{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"intervention":987,"totalTrials":144,"cells":1245},{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[],{"trials":1251,"activeCount":100},[1252],{"nctId":976,"briefTitle":977,"status":135,"phases":1253,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":1254,"interventions":1255},[90],[984],[967,986,987,988],{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"intervention":988,"totalTrials":144,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1265,"activeCount":100},[],{"trials":1267,"activeCount":100},[],{"trials":1269,"activeCount":100},[1270],{"nctId":976,"briefTitle":977,"status":135,"phases":1271,"primaryCompletion":979,"completion":980,"start":981,"enrollment":982,"conditions":1272,"interventions":1273},[90],[984],[967,986,987,988],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[],{"trials":1279,"activeCount":100},[],{"intervention":1281,"totalTrials":144,"cells":1282},"Oxaliplatin, Capecitabine",{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[1289],{"nctId":1290,"briefTitle":1291,"status":122,"phases":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1297},"NCT00220051","A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer",[90],"2001-11",109,[1296],"Rectal Cancer",[1281],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":100},[],{"intervention":1305,"totalTrials":144,"cells":1306},"Irinotecan, 5-Fluorouracil, Leucovorin",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":100},[],{"trials":1312,"activeCount":100},[1313],{"nctId":1314,"briefTitle":1315,"status":122,"phases":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT00220064","A Phase II Trial Evaluating Irinotecan Plus 5FU\u002FLV in Patients With Relapsed\u002FRefractory Upper GI Tumours",[90],"2005-11","2000-07",65,[890],[1305],{"trials":1323,"activeCount":100},[],{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[],{"intervention":1329,"totalTrials":144,"cells":1330},"Alemtuzumab",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1332,"activeCount":100},[],{"trials":1334,"activeCount":100},[],{"trials":1336,"activeCount":100},[1337],{"nctId":1338,"briefTitle":1339,"status":122,"phases":1340,"conditions":1341,"interventions":1343},"NCT00292760","A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion",[90],[1342],"Chronic Lymphocytic Leukaemia",[1329,1344],"Methyprednisolone",{"trials":1346,"activeCount":100},[],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"intervention":1344,"totalTrials":144,"cells":1352},{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[1359],{"nctId":1338,"briefTitle":1339,"status":122,"phases":1360,"conditions":1361,"interventions":1362},[90],[1342],[1329,1344],{"trials":1364,"activeCount":100},[],{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"intervention":1000,"totalTrials":144,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[1377],{"nctId":990,"briefTitle":991,"status":135,"phases":1378,"primaryCompletion":980,"completion":993,"start":994,"enrollment":995,"conditions":1379,"interventions":1380},[90],[997],[650,999,572,967,1000],{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"intervention":1388,"totalTrials":144,"cells":1389},"bevacizumab, Rituximab",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[1396],{"nctId":1397,"briefTitle":1398,"status":162,"phases":1399,"primaryCompletion":1400,"completion":1400,"start":910,"enrollment":1401,"conditions":1402,"interventions":1405},"NCT00788606","R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma",[90],"2010-06",7,[1403,1404],"Non-Hodgkin's Lymphoma","B-cell Lymphoma",[1388],{"trials":1407,"activeCount":100},[],{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":100},[],{"intervention":1413,"totalTrials":144,"cells":1414},"pentoxifylline",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[1421],{"nctId":1422,"briefTitle":1423,"status":122,"phases":1424,"start":1425,"conditions":1426,"interventions":1428},"NCT00022204","Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer",[90],"2000-01",[15,1427],"Lymphedema",[1413],{"trials":1430,"activeCount":100},[],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"intervention":1436,"totalTrials":144,"cells":1437},"Crizotinib Oral Capsule [Xalkori]",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1439,"activeCount":100},[],{"trials":1441,"activeCount":100},[],{"trials":1443,"activeCount":100},[1444],{"nctId":1445,"briefTitle":1446,"status":122,"phases":1447,"primaryCompletion":1448,"completion":1448,"start":1449,"enrollment":16,"conditions":1450,"interventions":1453},"NCT03620643","Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours",[90],"2024-08-30","2019-05-09",[1451,1091,687,1452],"Lobular Breast Carcinoma","CDH1 Gene Mutation",[1436,1454],"Fulvestrant 50 MG\u002FML Prefilled Syringe [Faslodex or generic]",{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"intervention":1454,"totalTrials":144,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1464,"activeCount":100},[],{"trials":1466,"activeCount":100},[],{"trials":1468,"activeCount":100},[1469],{"nctId":1445,"briefTitle":1446,"status":122,"phases":1470,"primaryCompletion":1448,"completion":1448,"start":1449,"enrollment":16,"conditions":1471,"interventions":1472},[90],[1451,1091,687,1452],[1436,1454],{"trials":1474,"activeCount":100},[],{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"intervention":1480,"totalTrials":144,"cells":1481},"ibrutinib",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[1488],{"nctId":1489,"briefTitle":1490,"status":135,"phases":1491,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":19,"conditions":1494,"interventions":1496},"NCT02884453","Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma",[90],"2021-12-30","2016-07-19",[1495],"Gastrooesophageal Cancer",[1480],{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":100},[],{"intervention":1017,"totalTrials":144,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[],{"trials":1510,"activeCount":100},[1511],{"nctId":1002,"briefTitle":1003,"status":135,"phases":1512,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1513,"interventions":1514},[90],[1010,1011,1012,1013,1014],[1016,650,1017,1018,1019,1020,967],{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"intervention":1018,"totalTrials":144,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1533,"PHASE4":1535,"NA":1537},{"trials":1524,"activeCount":100},[],{"trials":1526,"activeCount":100},[],{"trials":1528,"activeCount":100},[1529],{"nctId":1002,"briefTitle":1003,"status":135,"phases":1530,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1531,"interventions":1532},[90],[1010,1011,1012,1013,1014],[1016,650,1017,1018,1019,1020,967],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[],{"intervention":1019,"totalTrials":144,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[1547],{"nctId":1002,"briefTitle":1003,"status":135,"phases":1548,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1549,"interventions":1550},[90],[1010,1011,1012,1013,1014],[1016,650,1017,1018,1019,1020,967],{"trials":1552,"activeCount":100},[],{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":100},[],{"intervention":1558,"totalTrials":144,"cells":1559},"Epirubicin, Cisplatin, Capecitabine",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[1566],{"nctId":1567,"briefTitle":1568,"status":122,"phases":1569,"start":1570,"enrollment":22,"conditions":1571,"interventions":1573},"NCT00220129","Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With\u002FWithout Surgery for Squamous Cell Carcinoma of the Oesophagus",[90],"2002-11",[1572],"Oesophageal Carcinoma",[1558],{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"intervention":1581,"totalTrials":144,"cells":1582},"Tocovid SupraBio plus pentoxifylline",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1584,"activeCount":100},[],{"trials":1586,"activeCount":100},[],{"trials":1588,"activeCount":100},[1589],{"nctId":1590,"briefTitle":1591,"status":122,"phases":1592,"primaryCompletion":1593,"completion":1593,"start":1594,"enrollment":1595,"conditions":1596,"interventions":1598},"NCT02230800","PPALM-Palm Oil and Pentoxifylline Against Late Morbidity",[90],"2019-12-20","2014-11-25",62,[1597],"Long-term Adverse Effects of Radiotherapy for Pelvic Cancer",[1581],{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[],{"intervention":704,"totalTrials":144,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"trials":1612,"activeCount":100},[1613],{"nctId":695,"briefTitle":696,"status":135,"phases":1614,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":1615,"interventions":1616},[90],[18,702],[704,676],{"trials":1618,"activeCount":100},[],{"trials":1620,"activeCount":100},[],{"trials":1622,"activeCount":100},[],{"intervention":1624,"totalTrials":144,"cells":1625},"Depsipeptide",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[1632],{"nctId":1633,"briefTitle":1634,"status":135,"phases":1635,"enrollment":35,"conditions":1636,"interventions":1638},"NCT00299351","A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.",[90],[1637],"Peripheral T Cell Lymphoma (PTCL)",[1624],{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"intervention":1646,"totalTrials":144,"cells":1647},"Ethosuximide",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[1654],{"nctId":1655,"briefTitle":1656,"status":122,"phases":1657,"primaryCompletion":1658,"completion":1658,"start":1659,"enrollment":166,"conditions":1660,"interventions":1662},"NCT01278004","Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)",[90],"2014-07","2010-05",[18,1661],"Peripheral Neuropathy",[1646],{"trials":1664,"activeCount":100},[],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"intervention":1670,"totalTrials":144,"cells":1671},"Pegylated Interferon",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1687,"PHASE4":1689,"NA":1691},{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":100},[1678],{"nctId":1679,"briefTitle":1680,"status":122,"phases":1681,"completion":1682,"start":1683,"conditions":1684,"interventions":1685},"NCT00323505","A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma",[90],"2004-12","2001-03",[957],[1670,1686],"Interferon-alpha2a",{"trials":1688,"activeCount":100},[],{"trials":1690,"activeCount":100},[],{"trials":1692,"activeCount":100},[],{"intervention":1686,"totalTrials":144,"cells":1694},{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":100},[1701],{"nctId":1679,"briefTitle":1680,"status":122,"phases":1702,"completion":1682,"start":1683,"conditions":1703,"interventions":1704},[90],[957],[1670,1686],{"trials":1706,"activeCount":100},[],{"trials":1708,"activeCount":100},[],{"trials":1710,"activeCount":100},[],{"intervention":1712,"totalTrials":144,"cells":1713},"sargramostim",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[1720],{"nctId":1721,"briefTitle":1722,"status":122,"phases":1723,"completion":1037,"start":1724,"conditions":1725,"interventions":1728},"NCT00004256","Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer",[90],"1997-10",[24,1726,1727],"Oral Complications","Radiation Toxicity",[1712],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"trials":1734,"activeCount":100},[],{"intervention":1736,"totalTrials":144,"cells":1737},"epirubicin, capecitabine, cisplatin",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[1744],{"nctId":1745,"briefTitle":1746,"status":122,"phases":1747,"start":1570,"enrollment":982,"conditions":1748,"interventions":1750},"NCT00220103","Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma",[90],[1749],"Adenocarcinoma of Oesophagus",[1736],{"trials":1752,"activeCount":100},[],{"trials":1754,"activeCount":100},[],{"trials":1756,"activeCount":100},[],{"intervention":1758,"totalTrials":144,"cells":1759},"Adjuvant Chemotherapy",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":100},[],{"trials":1765,"activeCount":100},[1766],{"nctId":1767,"briefTitle":1768,"status":135,"phases":1769,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1775},"NCT01047969","Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy",[90],"2019-06","2006-06-06",99,[1774],"Rectal Adenocarcinoma",[1758],{"trials":1777,"activeCount":100},[],{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"intervention":1783,"totalTrials":144,"cells":1784},"Talimogene laherparepvec",{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[1791],{"nctId":1792,"briefTitle":1793,"status":122,"phases":1794,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":166,"conditions":1797,"interventions":1799},"NCT03555032","TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)",[89,90],"2021-08-01","2018-06-26",[1798],"Melanoma and Sarcoma",[1783],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"intervention":1807,"totalTrials":144,"cells":1808},"Compound 451238",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":100},[],{"trials":1814,"activeCount":100},[1815],{"nctId":1816,"briefTitle":1817,"status":122,"phases":1818,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1822,"interventions":1824},"NCT03602833","Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma",[89,90],"2023-06-30","2018-11-05",12,[1823],"Soft-tissue Sarcoma",[1807],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"intervention":1832,"totalTrials":144,"cells":1833},"Gemcitabine 1000 mg\u002Fm2 iv days 1, 8, 15 of a 28 day cycle",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[],{"trials":1839,"activeCount":100},[1840],{"nctId":1841,"briefTitle":1842,"status":122,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1317,"enrollment":1845,"conditions":1846,"interventions":1848},"NCT00260364","Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer",[89,90],"2011-08",44,[1847],"Pancreatic Cancer",[1832,1849,1850,1851],"Capecitabine orally days 1 -21","Erlotinib 100 mg orally days 1-28","Bevacizumab 5 mg\u002Fkg intravenously every 2 weeks",{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[],{"trials":1857,"activeCount":100},[],{"intervention":1849,"totalTrials":144,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1861,"activeCount":100},[],{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":100},[1866],{"nctId":1841,"briefTitle":1842,"status":122,"phases":1867,"primaryCompletion":1844,"completion":1844,"start":1317,"enrollment":1845,"conditions":1868,"interventions":1869},[89,90],[1847],[1832,1849,1850,1851],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"intervention":1850,"totalTrials":144,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":100},[1884],{"nctId":1841,"briefTitle":1842,"status":122,"phases":1885,"primaryCompletion":1844,"completion":1844,"start":1317,"enrollment":1845,"conditions":1886,"interventions":1887},[89,90],[1847],[1832,1849,1850,1851],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"trials":1893,"activeCount":100},[],{"intervention":1851,"totalTrials":144,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[1902],{"nctId":1841,"briefTitle":1842,"status":122,"phases":1903,"primaryCompletion":1844,"completion":1844,"start":1317,"enrollment":1845,"conditions":1904,"interventions":1905},[89,90],[1847],[1832,1849,1850,1851],{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"intervention":1193,"totalTrials":144,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1924,"PHASE4":1926,"NA":1928},{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[1920],{"nctId":1186,"briefTitle":1187,"status":122,"phases":1921,"completion":137,"start":1189,"conditions":1922,"interventions":1923},[90],[15],[1192,1193,1194,1195,1196],{"trials":1925,"activeCount":100},[],{"trials":1927,"activeCount":100},[],{"trials":1929,"activeCount":100},[],{"intervention":1194,"totalTrials":144,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1933,"activeCount":100},[],{"trials":1935,"activeCount":100},[],{"trials":1937,"activeCount":100},[1938],{"nctId":1186,"briefTitle":1187,"status":122,"phases":1939,"completion":137,"start":1189,"conditions":1940,"interventions":1941},[90],[15],[1192,1193,1194,1195,1196],{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":100},[],{"trials":1947,"activeCount":100},[],{"intervention":1195,"totalTrials":144,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1951,"activeCount":100},[],{"trials":1953,"activeCount":100},[],{"trials":1955,"activeCount":100},[1956],{"nctId":1186,"briefTitle":1187,"status":122,"phases":1957,"completion":137,"start":1189,"conditions":1958,"interventions":1959},[90],[15],[1192,1193,1194,1195,1196],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":100},[],{"intervention":1196,"totalTrials":144,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":100},[],{"trials":1973,"activeCount":100},[1974],{"nctId":1186,"briefTitle":1187,"status":122,"phases":1975,"completion":137,"start":1189,"conditions":1976,"interventions":1977},[90],[15],[1192,1193,1194,1195,1196],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":100},[],{"intervention":131,"totalTrials":144,"cells":1985},{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":100},[],{"trials":1991,"activeCount":100},[1992],{"nctId":120,"briefTitle":121,"status":122,"phases":1993,"primaryCompletion":124,"completion":108,"start":125,"enrollment":126,"conditions":1994,"interventions":1995},[90],[128],[56,130,131],{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[],{"trials":2001,"activeCount":100},[],{"intervention":2003,"totalTrials":144,"cells":2004},"Vargatef",{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2022,"PHASE4":2024,"NA":2026},{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[2011],{"nctId":2012,"briefTitle":2013,"status":563,"phases":2014,"primaryCompletion":2015,"completion":2015,"start":2016,"enrollment":100,"conditions":2017,"interventions":2020},"NCT03361319","Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma",[89,90],"2023-07","2020-07",[2018,2019],"NSCLC, Recurrent","Adenocarcinoma of Lung",[2003,2021],"Abraxane",{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[],{"trials":2027,"activeCount":100},[],{"intervention":2021,"totalTrials":144,"cells":2029},{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[2036],{"nctId":2012,"briefTitle":2013,"status":563,"phases":2037,"primaryCompletion":2015,"completion":2015,"start":2016,"enrollment":100,"conditions":2038,"interventions":2039},[89,90],[2018,2019],[2003,2021],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":100},[],{"trials":2045,"activeCount":100},[],{"intervention":2047,"totalTrials":144,"cells":2048},"AZD 4547",{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[2055],{"nctId":2056,"briefTitle":2057,"status":135,"phases":2058,"primaryCompletion":2059,"completion":2060,"start":2061,"enrollment":2062,"conditions":2063,"interventions":2065},"NCT01795768","Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours",[90],"2014-09","2015-09","2012-09",48,[1091,1089,15,2064],"Squamous Cell Carcinoma of the Lung",[2047],{"trials":2067,"activeCount":100},[],{"trials":2069,"activeCount":100},[],{"trials":2071,"activeCount":100},[],{"intervention":2073,"totalTrials":144,"cells":2074},"patent blue V dye",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[2081],{"nctId":2082,"briefTitle":2083,"status":135,"phases":2084,"start":2085,"conditions":2086,"interventions":2087},"NCT00005821","Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer",[90],"1998-12",[15],[2073],{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[],{"intervention":2095,"totalTrials":144,"cells":2096},"Methotrexate",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2098,"activeCount":100},[],{"trials":2100,"activeCount":100},[],{"trials":2102,"activeCount":100},[2103],{"nctId":2104,"briefTitle":2105,"status":162,"phases":2106,"primaryCompletion":2059,"completion":2059,"start":2107,"enrollment":599,"conditions":2108,"interventions":2110},"NCT00952016","Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency",[90],"2009-02",[2109],"Advanced Colorectal Cancer",[2095],{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":100},[],{"intervention":2118,"totalTrials":144,"cells":2119},"FLOT-A",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2121,"activeCount":100},[],{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[2126],{"nctId":2127,"briefTitle":2128,"status":135,"phases":2129,"primaryCompletion":2130,"completion":2131,"start":2132,"enrollment":1845,"conditions":2133,"interventions":2136},"NCT03399071","Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer",[90],"2022-11-01","2025-08-15","2017-07-31",[2134,2135],"Gastric Adenocarcinoma","Oesophageal Adenocarcinoma",[2118],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"intervention":2144,"totalTrials":144,"cells":2145},"AZD6738",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2147,"activeCount":100},[],{"trials":2149,"activeCount":100},[2150],{"nctId":2151,"briefTitle":2152,"status":135,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":1658,"enrollment":1008,"conditions":2155,"interventions":2157},"NCT02223923","Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours",[89],"2025-12-30",[2156],"Solid Tumour Refractory to Conventional Treatment",[2144],{"trials":2159,"activeCount":100},[],{"trials":2161,"activeCount":100},[],{"trials":2163,"activeCount":100},[],{"trials":2165,"activeCount":100},[],{"intervention":571,"totalTrials":144,"cells":2167},{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[2172],{"nctId":561,"briefTitle":562,"status":563,"phases":2173,"primaryCompletion":565,"completion":566,"start":567,"enrollment":100,"conditions":2174,"interventions":2175},[89],[569],[571,46,572],{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":100},[],{"trials":2181,"activeCount":100},[],{"trials":2183,"activeCount":100},[],{"intervention":2185,"totalTrials":144,"cells":2186},"CCT3833",{"EARLY_PHASE1":2187,"PHASE1":2189,"PHASE2":2201,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2188,"activeCount":100},[],{"trials":2190,"activeCount":100},[2191],{"nctId":2192,"briefTitle":2193,"status":122,"phases":2194,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":2198,"conditions":2199,"interventions":2200},"NCT02437227","Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833",[89],"2017-12","2018-07","2015-04-15",31,[667,18],[2185],{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[],{"trials":2206,"activeCount":100},[],{"trials":2208,"activeCount":100},[],{"intervention":1077,"totalTrials":144,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[2215],{"nctId":1067,"briefTitle":1068,"status":122,"phases":2216,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":634,"conditions":2217,"interventions":2218},[89],[1074],[1076,1077],{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":100},[],{"trials":2224,"activeCount":100},[],{"trials":2226,"activeCount":100},[],{"intervention":2228,"totalTrials":144,"cells":2229},"AZD2014 3 on\u002F4 off & weekly paclitaxel",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2231,"activeCount":100},[],{"trials":2233,"activeCount":100},[2234],{"nctId":2235,"briefTitle":2236,"status":122,"phases":2237,"primaryCompletion":2238,"completion":2238,"start":2239,"enrollment":2240,"conditions":2241,"interventions":2242},"NCT02193633","A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.",[89],"2017-11-15","2013-04-26",90,[1074],[2228,2243],"AZD2014 2 on\u002F5 off & weekly paclitaxel",{"trials":2245,"activeCount":100},[],{"trials":2247,"activeCount":100},[],{"trials":2249,"activeCount":100},[],{"trials":2251,"activeCount":100},[],{"intervention":2243,"totalTrials":144,"cells":2253},{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2262,"PHASE3":2264,"PHASE4":2266,"NA":2268},{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[2258],{"nctId":2235,"briefTitle":2236,"status":122,"phases":2259,"primaryCompletion":2238,"completion":2238,"start":2239,"enrollment":2240,"conditions":2260,"interventions":2261},[89],[1074],[2228,2243],{"trials":2263,"activeCount":100},[],{"trials":2265,"activeCount":100},[],{"trials":2267,"activeCount":100},[],{"trials":2269,"activeCount":100},[],{"intervention":1042,"totalTrials":144,"cells":2271},{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[2276],{"nctId":1034,"briefTitle":1035,"status":122,"phases":2277,"primaryCompletion":124,"completion":124,"start":1037,"enrollment":1038,"conditions":2278,"interventions":2279},[89],[1040],[650,130,1042],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[],{"trials":2287,"activeCount":100},[],{"intervention":622,"totalTrials":144,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2298,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[2294],{"nctId":613,"briefTitle":614,"status":162,"phases":2295,"primaryCompletion":616,"completion":616,"start":617,"enrollment":96,"conditions":2296,"interventions":2297},[89],[619,620],[46,622],{"trials":2299,"activeCount":100},[],{"trials":2301,"activeCount":100},[],{"trials":2303,"activeCount":100},[],{"trials":2305,"activeCount":100},[],{"intervention":2307,"totalTrials":144,"cells":2308},"ONX-0801",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[2313],{"nctId":2314,"briefTitle":2315,"status":122,"phases":2316,"primaryCompletion":2317,"completion":2318,"start":994,"enrollment":2319,"conditions":2320,"interventions":2322},"NCT02360345","Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly",[89],"2020-01","2021-03",111,[2321],"Solid Tumours",[2307],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":100},[],{"intervention":2332,"totalTrials":144,"cells":2333},"Palbociclib + Taselisib \u002F Pictilisib",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[2338],{"nctId":2339,"briefTitle":2340,"status":122,"phases":2341,"primaryCompletion":2342,"completion":2343,"start":2344,"enrollment":2345,"conditions":2346,"interventions":2348},"NCT02389842","PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib",[89],"2018-10-31","2021-05-26","2015-03-25",79,[2347,15],"Advanced Solid Tumours",[2332],{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"intervention":2358,"totalTrials":144,"cells":2359},"VS-6766",{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":100},[2364],{"nctId":2365,"briefTitle":2366,"status":122,"phases":2367,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":2370,"conditions":2371,"interventions":2372},"NCT02407509","Phase I Trial of VS-6766 Alone and in Combination With Everolimus",[89],"2025-10-15","2013-06-17",104,[2321,957,30,32],[2358,2373],"Everolimus",{"trials":2375,"activeCount":100},[],{"trials":2377,"activeCount":100},[],{"trials":2379,"activeCount":100},[],{"trials":2381,"activeCount":100},[],{"intervention":2373,"totalTrials":144,"cells":2383},{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2398},{"trials":2385,"activeCount":100},[],{"trials":2387,"activeCount":100},[2388],{"nctId":2365,"briefTitle":2366,"status":122,"phases":2389,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":2370,"conditions":2390,"interventions":2391},[89],[2321,957,30,32],[2358,2373],{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[],{"intervention":650,"totalTrials":2401,"cells":2402},6,{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2411,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[2407],{"nctId":1034,"briefTitle":1035,"status":122,"phases":2408,"primaryCompletion":124,"completion":124,"start":1037,"enrollment":1038,"conditions":2409,"interventions":2410},[89],[1040],[650,130,1042],{"trials":2412,"activeCount":100},[2413,2417,2421,2425],{"nctId":642,"briefTitle":643,"status":122,"phases":2414,"primaryCompletion":645,"completion":645,"start":646,"enrollment":186,"conditions":2415,"interventions":2416},[89,90],[648],[46,650],{"nctId":990,"briefTitle":991,"status":135,"phases":2418,"primaryCompletion":980,"completion":993,"start":994,"enrollment":995,"conditions":2419,"interventions":2420},[90],[997],[650,999,572,967,1000],{"nctId":1002,"briefTitle":1003,"status":135,"phases":2422,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":2423,"interventions":2424},[90],[1010,1011,1012,1013,1014],[1016,650,1017,1018,1019,1020,967],{"nctId":2426,"briefTitle":2427,"status":122,"phases":2428,"start":2429,"enrollment":22,"conditions":2430,"interventions":2431},"NCT00220155","Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer",[90],"2004-05",[27],[650],{"trials":2433,"activeCount":100},[],{"trials":2435,"activeCount":100},[],{"trials":2437,"activeCount":100},[2438],{"nctId":2439,"briefTitle":2440,"status":122,"phases":2441,"enrollment":2442,"conditions":2443,"interventions":2445},"NCT00301301","A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma (DLBCL)",[],39,[2444],"Non-Hodgkins Lymphoma",[650,2446,572],"Cisplatinum",{"intervention":572,"totalTrials":96,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2457,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2450,"activeCount":100},[],{"trials":2452,"activeCount":100},[2453],{"nctId":561,"briefTitle":562,"status":563,"phases":2454,"primaryCompletion":565,"completion":566,"start":567,"enrollment":100,"conditions":2455,"interventions":2456},[89],[569],[571,46,572],{"trials":2458,"activeCount":100},[2459],{"nctId":990,"briefTitle":991,"status":135,"phases":2460,"primaryCompletion":980,"completion":993,"start":994,"enrollment":995,"conditions":2461,"interventions":2462},[90],[997],[650,999,572,967,1000],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[],{"trials":2468,"activeCount":100},[2469],{"nctId":2439,"briefTitle":2440,"status":122,"phases":2470,"enrollment":2442,"conditions":2471,"interventions":2472},[],[2444],[650,2446,572],{"intervention":2474,"totalTrials":599,"cells":2475},"Cetuximab",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2486,"PHASE4":2488,"NA":2490},{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"trials":2481,"activeCount":100},[2482],{"nctId":133,"briefTitle":134,"status":135,"phases":2483,"start":137,"enrollment":138,"conditions":2484,"interventions":2485},[90],[27],[141,142,143],{"trials":2487,"activeCount":100},[],{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[2492],{"nctId":2493,"briefTitle":2494,"status":122,"phases":2495,"primaryCompletion":2496,"completion":2496,"start":2497,"enrollment":126,"conditions":2498,"interventions":2499},"NCT02994888","PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer",[],"2016-12","2012-11",[128],[2474],{"intervention":2501,"totalTrials":144,"cells":2502},"Regorafenib",{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2504,"activeCount":100},[],{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[2515],{"nctId":2516,"briefTitle":2517,"status":122,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2524},"NCT03010722","Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy",[],"2017-01","2017-07","2015-01",49,[128],[2501],{"intervention":2526,"totalTrials":144,"cells":2527},"gadolinium-chelate",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[],{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":100},[],{"trials":2539,"activeCount":100},[2540],{"nctId":2541,"briefTitle":2542,"status":135,"phases":2543,"primaryCompletion":2544,"start":2545,"enrollment":2546,"conditions":2547,"interventions":2548},"NCT00602316","Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer",[93],"2009-09","2007-11",20,[15],[2526],{"intervention":2550,"totalTrials":144,"cells":2551},"gene expression analysis",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2553,"activeCount":100},[],{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[2564],{"nctId":2565,"briefTitle":2566,"status":122,"phases":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2571},"NCT00081003","Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer",[93],"2003-11",1000,[15],[2550,2572],"protein expression analysis",{"intervention":2572,"totalTrials":144,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[2587],{"nctId":2565,"briefTitle":2566,"status":122,"phases":2588,"start":2568,"enrollment":2569,"conditions":2589,"interventions":2590},[93],[15],[2550,2572],{"intervention":2592,"totalTrials":144,"cells":2593},"Protective analgesia",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":100},[],{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[2606],{"nctId":2607,"briefTitle":2608,"status":135,"phases":2609,"primaryCompletion":2610,"completion":980,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2617},"NCT02170415","Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery",[93],"2017-02","2014-06",154,[2614,2615,2616],"Persistent Post-surgical Pain","Neuropathic Pain","Cancer Pain",[2592],{"intervention":2446,"totalTrials":144,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[2632],{"nctId":2439,"briefTitle":2440,"status":122,"phases":2633,"enrollment":2442,"conditions":2634,"interventions":2635},[],[2444],[650,2446,572]]